A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Name: A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
Published: 2024
License: Public Domain

Jules Bordet Institute · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

multiple-myeloma

multiple myeloma, refractory, multiple myeloma in relapse, multiple myeloma progression, multiple myeloma, somatostatin receptor, radionuclide therapy, actinium-225, targeted alpha therapy, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Related documents